SMO/AKT/ NF2/CDK INHIBITORS FOR PROGRESSIVE MENINGIOMAS

A Phase 2 open label trial that studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and Capivasertib work in treating patients with progressive Meningioma.